# The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review

## TL;DR

This review explores the potential of cardiac myosin inhibitors as a new treatment option for hypertrophic cardiomyopathy.

## Contribution

The paper provides a scoping review of emerging cardiac myosin inhibitors as a novel pharmacological therapy for HCM.

## Key findings

- Cardiac myosin inhibitors are safe and effective as a second-line treatment for HCM.
- Ongoing studies may establish CMIs as part of standard HCM treatment in the future.

## Abstract

Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and interventional therapies. This scoping review aimed to summarize the traditional therapeutic options for HCM and to explore emerging research on novel cardiac myosin inhibitors (CMIs) as a new option for pharmacologic management of HCM. A PRISMA search strategy was carried out to identify the pertinent literature on mavacamten and aficamten—two novel CMIs. Seventeen studies were included. Based on the results of the studies included in this review, cardiac myosin inhibitors have been proven to be a safe and efficacious second-line option for the management of HCM. In the foreseeable future, based on results of ongoing studies investigating patient outcomes and side-effect profile, CMIs may potentially play a larger role as part of standard treatment of HCM.